Twist Bioscience Rule 144 Notice: 235-Share Sale After Vesting

Rhea-AI Filing Summary

Form 144 notice from Robert Werner regarding Twist Bioscience (TWST)

The filing reports a proposed public sale of 235 shares of TWST common stock through Fidelity Brokerage Services with an approximate aggregate market value of $6,053.58, slated for 09/08/2025. Those 235 shares were acquired via restricted stock vesting on 09/05/2025 and paid as compensation. The filing lists TWST’s shares outstanding as 60,360,925. The filer also disclosed sales during the prior three months totaling 1,277 shares on 08/04, 08/21 and 08/25 with combined gross proceeds of $34,075.88. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Full Rule 144 disclosure provided with acquisition date, nature of acquisition, broker and planned sale date
• Transaction size is de minimis relative to the 60,360,925 shares outstanding
• Prior sales were disclosed, indicating transparent reporting of recent dispositions

Negative

• Insider sold 1,277 shares in the past three months, which may warrant monitoring though not material in size

Insights

Securities Analyst

TL;DR: Routine insider sale of a very small stake following restricted stock vesting; immaterial to capitalization.

The filing documents a small, post-vesting sale of 235 shares valued at about $6k, filed under Rule 144 and executed through a brokerage. Compared with the reported 60.36 million shares outstanding, the proposed sale is de minimis and unlikely to affect market valuation or control. Prior August sales totaling 1,277 shares are disclosed, showing recent, modest disposition activity by the same person. This appears to be a standard compliance disclosure rather than a material corporate event.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; no governance red flags from the notice alone.

The form provides required details: acquisition date (09/05/2025), nature of acquisition (restricted stock vesting), payment as compensation, and broker routing. The signer affirms absence of undisclosed material adverse information, and the filing lists recent insider sales. There is no information in the notice indicating governance issues, executive departures, or regulatory problems. Documentation appears complete for a routine restricted-share disposition.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	235	6053.58	60360925	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Restricted Stock Vesting	Issuer			235	09/05/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Robert Werner 681 Gateway Blvd South San Francisco CA 94080	Common	08/04/2025	186	5275.72
Robert Werner 681 Gateway Blvd South San Francisco CA 94080	Common	08/21/2025	238	6179.48
Robert Werner 681 Gateway Blvd South San Francisco CA 94080	Common	08/25/2025	853	23620.68

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for TWST report?

The Form 144 reports a proposed sale of 235 TWST common shares via Fidelity on 09/08/2025 with an aggregate market value of $6,053.58.

How were the 235 shares acquired according to the filing?

The filing states the shares were acquired on 09/05/2025 through restricted stock vesting and the payment is listed as compensation.

How many TWST shares are outstanding per the notice?

The Form 144 lists 60,360,925 shares outstanding.

Were there any insider sales by the same person recently?

Yes. The filer disclosed three sales in August 2025: 186 shares on 08/04, 238 shares on 08/21, and 853 shares on 08/25, totaling 1,277 shares and gross proceeds of $34,075.88.

Does the Form 144 indicate undisclosed material information about Twist Bioscience?

By signing, the person represents they do not know of any material adverse information not publicly disclosed. The filing itself contains no statement of undisclosed material information.